Diabetes Technol Ther 2006;8:636-43
The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption
Jandee S, Geeraerts A, Geysen H, Rommel N, Tack J, Vanuytsel T
At my last doctors visit, my A1C levels were lower, which was a huge relief
This stress is shown by the overexpression of iNOS, an enzyme primarily involved in the mitochondrial lipid peroxidation, with consequent damage of the cell membrane, which is validated by the accumulation of intracellular MDA: a hallmark of lipoperoxidation
&srotate=0)
